

# *Kaempferia parviflora* EXTRACT INHIBITS CASPASE-DEPENDENT APOPTOSIS STIMULATED BY *H. pylori* INFECTION

Variya Nemidkanam, Nuntaree Chaichanawongsaroj\*

Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, 10330, Thailand

## ABSTRACT:

**Background:** Apoptosis process is one of the major pathogenesis in gastric cancer causing by *Helicobacter pylori* infection. *Kaempferia parviflora* (KP) has been traditionally used for treating gastrointestinal tract disorders, which exhibited anti-*Helicobacter pylori*, anti-inflammatory and anti-gastric ulcer. Our study aimed to evaluate the anti-apoptosis effects of KP extract in *H. pylori*-infected gastric epithelial cells.

**Methods:** The cytotoxic effect of KP extract was assessed by MTT assay in AGS cells at various concentrations and incubation times. The level of caspase-8 and caspase-3/7 activities and DNA fragmentation were determined by luminescence assays and ELISA, respectively.

**Results:** KP ethyl acetate extract significantly decreased AGS cells viability in dose and time-dependent manners, no cytotoxic effect was observed at 8 and 16 µg/ml of KP extract even 24 hours. *H. pylori* activated apoptosis mainly via caspase-3/7 more effectively than caspase-8. Interestingly, KP extract significantly inhibited both caspase-3/7 and caspase-8 in *H. pylori* infected and uninfected cells, although DNA fragmentation was not suppressed.

**Conclusions:** Thus, KP extract may be a prominent alternative therapy for gastric cancer induced by *H. pylori* infection through the inhibition of initiator caspase-8 and effector caspase-3/7 which play important roles in apoptosis pathway.

**Keywords:** *Helicobacter pylori*; *Kaempferia parviflora*; Apoptosis; Caspase-3/7; Caspase-8; DNA fragmentation

DOI: 10.14456/jhr.2017.66

Received: July 2017; Accepted: August 2017

## INTRODUCTION

*Helicobacter pylori* is a causative agent of gastritis, gastric ulcer, mucosa-associated lymphoid tissue lymphoma and gastric cancer. The WHO classification indicated that *H. pylori* is a class I carcinogen. The majority of people in the world are infected by *H. pylori* which the highest prevalence area is in the southeast Asia [1]. In this region, there is difference prevalent rate in each country, Vietnam is about 75% [2] which is the highest rate and Thailand is about 57% [3]. Because *H. pylori* infection is a major cause of gastritis and gastric cancer, serious concerns aim at killing the organism

with antibiotics and prevention of gastric cancer. Antibiotic is the primary eradication therapy which clarithromycin and metronidazole combination is still used in first-line therapy [4]. Unfortunately, many *H. pylori* antimicrobial drugs resistance strains dramatically increase which results in persistent infection and subsequently develops to gastric cancer [5]. The first step of *H. pylori* infection begins with the agent colonization to gastric mucosa; its virulent factors such as cytotoxin-associated protein A (CagA) massively activate the immune responsiveness in host gastric cells by secretion of certain cytokines and chemokines. The immune modulatory in gastric cells trigger aberrant proliferation and apoptosis [6].

Apoptosis pathway composes of extrinsic (death

\* Correspondence to: Nuntaree Chaichanawongsaroj  
E-mail: nuntaree@gmail.com

## Cite this article as:

Nemidkanam V, Chaichanawongsaroj N. *Kaempferia parviflora* extract inhibits caspase-dependent apoptosis stimulated by *H. pylori* infection. J Health Res. 2017; 31(Suppl.1): S41-9. DOI: 10.14456/jhr.2017.66

receptor-mediated) and intrinsic (mitochondria-mediated) pathway. The products of inflammatory response could stimulate apoptosis pathway through death ligand receptor or p53 activation such as TNF-alpha from macrophages [7] and reactive oxygen species produced by polymorphonuclear white blood cells [8], respectively. Moreover, vacuolating toxin A (VacA) from *H. pylori* could stimulate Bax and cytochrome c release in mitochondria-mediated pathway [9, 10]. Each caspase enzyme family plays important role in apoptosis process in different pathways, which subsequently activate endonuclease enzyme to produce DNA fragmentation, a key feature of apoptosis. The caspase-8 and caspase-10 implicate with apoptosis by death receptor-mediated pathway. The caspase-9 activation is a signaling of mitochondria-mediated pathway. The caspase-3/7 involves in both extrinsic and intrinsic pathways. A higher apoptosis index was found in gastric carcinoma than non-ulcer dyspepsia in patients infected with *H. pylori* [11]. Inflammation mediated by *H. pylori* infection also participates in cell apoptosis via leukocyte activities, especially ROS production [12-14]. The apoptotic and proliferation indices were increased and correlated to the severity of gastric inflammation in *H. pylori* induced gastritis [15]. Finally, cell apoptosis develops chronic gastritis to gastric atrophy stage and intestinal metaplasia [16, 17] and DNA might lose its stability leading to cell transformation and over proliferation which finally causes gastric cancer [18]. Thus, apoptosis is an important cell response *H. pylori* infection which participates in the gastric pathogenesis and early stage of carcinogenesis.

According to the ineffective regimens for treating *H. pylori*, natural substances have been used as alternative therapy in many countries, which have effective activities and low cytotoxicity. Several medicinal plants have been traditionally used for gastric ailments for many centuries in many countries such as Greek [19], India [20] and Thailand [21]. The prominent anti-*H. pylori* activity was founded in several herbal medicines including curcumin, garlic extract, ginger, and ginseng [22-25]. The Thai ginseng or *Kaempferia parviflora* (KP) also known as Krachaidum (in Thai) is a medicinal plant belong to *Zingiberaceae* family. The superior of pharmacological activities of KP has been demonstrated including antiallergenic, anti-inflammatory, antimutagenic, antimicrobial, anticancer and anti-peptic ulcer [26]. In previous

study, KP could reduce TNF-alpha, nitric oxide and prostaglandin production of inflammatory cells [27]. KP extract has anti-gastric ulcer and anti-*H. pylori* activities including the inhibitory effects against *H. pylori* growth, anti-adhesion and anti-internalization into HEp-2 cell [28, 29]. However, the anti-carcinogenesis effects of KP are obscure in *H. pylori*-infected gastric cells. Hence, in the present study, we determined the anti-apoptosis effects of KP extract on *H. pylori* infected AGS cells including DNA fragmentation, caspase-3/7 and caspase-8 activities. The benefit of *H. pylori* eradication using traditional therapy of KP extract will be explored in the aspect of apoptotic responses which may improve eradication rate and reduce gastric cancer.

## MATERIALS AND METHODS

### Plant materials and extraction

A voucher specimen of *Kaempferia parviflora* Wall. Ex Baker was authenticated under ES280306, which deposited at the herbarium of the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand. The extraction process was described previously [29]. Briefly, roughly ground air-dried KP was extracted twice with 200 ml ethyl acetate solution for 48 hours at room temperature. The filtrate was evaporated at 40°C to dryness and dissolved at 10 mg/ml or 100 mg/ml with dimethyl sulfoxide (DMSO). The stock solutions were sterile by 0.2 µm pore size filter and stored at -20 °C in the dark.

### Bacterial stain, culture condition and inoculum preparation

*H. pylori* ATCC 43504 (vacA s1a/ml, cagA positive) strain was cultured on 7% (v/v) sheep blood enriched with brain heart infusion agar (Oxoid, United Kingdom) and incubated at 37°C for 3 days in anaerobic jar with Gas Pack (Anaero Pack-MicroAero, Japan) to create microaerobic condition (6-12% O<sub>2</sub> and 5-8% CO<sub>2</sub>). The inoculum was prepared in cell culture medium and adjusted to 1x10<sup>8</sup> CFU/ml by Densitometer (Biomérieux Biotechnology, France).

### AGS cells culture

AGS cells or human gastric adenocarcinoma epithelial cells (ATCC CRL1739) was kindly provided by Assist. Prof. Dr. Panan Rattawongjirakul, Faculty of Allied Health Sciences, Chulalongkorn University, Thailand. The cells were cultured in RPMI 1640 medium (Caisson Laboratories, USA) containing 10% fetal bovine serum (Caisson Laboratories,

USA) and 1% antibiotic/antimycotic (Capricorn Scientific, Germany) at 37°C in 5% CO<sub>2</sub> and 80% humidity. AGS cells with 80-90% confluency were harvested by 0.5% trypsin (Caisson Laboratories, USA).

#### Cell viability assay

AGS cells were seeded in 96-well plate at a density of 1x10<sup>4</sup> cells/well and incubated overnight. After the cells attached, the medium was removed and the cells were incubated in RPMI 1640 containing two-fold serial dilution of the KP extract (8-128 µg/ml). For vehicle control, DMSO was tested instead of the extracts. The cytotoxic effects were examined at various times of 6, 12 and 24 hours. Five milligrams per milliliter of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Bio Basic INC., Canada) was added and incubated in the darkness at 37°C for 4 hours. Then, formazan crystals were solubilized in DMSO for 5 minutes and read absorbance at 570 nm and 630 nm for reference wavelength with a microplate reader (Synergy HT, BioTek). The % cell viability was calculated comparing to untreated AGS cells (Negative control) by the formula below.

$$\%Viability = \left[ \frac{\text{Mean absorbance test}}{\text{Mean absorbance control}} \right]_{570} - \left[ \frac{\text{Mean absorbance test}}{\text{Mean absorbance control}} \right]_{630} \times 100$$

#### Determination of caspase-3/7 and caspase-8

AGS cells were seeded in 96-well plate at a density of 1x10<sup>4</sup> cells/well and incubated overnight to reach 70 - 80% confluence. Three culture conditions were undertaken in the assay. Co-culture condition, AGS cells were infected with 3 days old *H. pylori* (Multiplicity of Infection, MOI = 1:100) and treated with KP extract at various times of 6, 12 and 24 hours. Pre-treated condition, AGS cells were incubated with the KP extract for 3 and 6 hours and then washed with 1X PBS before infected with *H. pylori* for more 3 and 6 hours. Pre-infected condition, AGS cells were infected with *H. pylori* for 3 and 6 hours and then washed with 1X PBS before incubated with the KP extract for more 3 and 6 hours. Vehicle control was treated with DMSO. The level of caspase-3/7 and caspase-8 activities were determined by Caspase-Glo® 3/7 and Caspase-Glo® 8 luminescence assay kit (Promega Corporation, USA). The subsequent steps were performed according to the manufacturer's instructions. Briefly, 100 µl of Caspase-Glo® 3/7 or Caspase-Glo® 8 reagents was added to each well, incubated at room temperature for 30 minutes and measured with luminometer microplate reader

(Synergy HT, BioTek).

#### Determination of DNA fragmentation

AGS cells were seeded in 96-well plate at a density of 1x10<sup>4</sup> cells/

well and incubated overnight. Cells were infected with 3 days old *H. pylori* (MOI = 1:100) and co-cultured with the extract for 6, 12 and 24 hours. After washing twice with 1X PBS, cells were lysed and centrifuged at 20,000× g for 10 minutes. The 100 µl of supernatant was added to each well of anti-histone coated microtiter plate supply in Cell Death Detection ELISAPLUS (Roche Ltd, Switzerland) kit. The plate was incubated for 90 minutes in the darkness and washed three times with washing buffer. The peroxidase conjugated mouse monoclonal antibody against DNA was added, incubated for 90 minutes and washed three times. One hundred microliters of substrate solution was added, incubated for 15 minutes on rotary shaker and measured the absorbance at 405 nm with a microplate reader (Synergy HT, BioTek). The released of enrichment factor of mono- and oligonucleosomes was calculated by the formula below.

$$\text{Enrichment factor} = \frac{(\text{Mean absorbance sample})}{(\text{Mean absorbance negative control})}$$


#### Statistical analysis

The data are presented as mean ± standard deviation (SD). Statistical analyses were performed using SPSS version 22.0 (IBM Corp, 2013). All data was analyzed by using one-way ANOVA statistical analysis and followed by Dunnett's post hoc test. The symbol \* indicates statistical significant (*p*-value < 0.05).

## RESULTS

#### Effect of KP extract on AGS cell viability

The growth inhibitory activity against *H. pylori* was confirmed in our KP ethyl acetate extract with MIC at 32 µg/ml (data not shown). Thus, the AGS cell viability was tested with KP extract ranging from 8-128 µg/ml using MTT assay. The KP extract at 8 and 16 µg/ml were not affected the cell viability after 6, 12 and 24 hours of incubation. At 6 hours, the cell viability was significantly reduced to 19.38% in KP extract at 128 µg/ml (Figure 1A). While, KP extract ranging from 32-128 µg/ml significantly decreased cell viability to 64.8%-1.7% at 12 hours and 54.2%-0.97% at 24 hours, respectively (Figure 1B and 1C). The highest concentration of 0.128% DMSO containing in



**Figure 1** Influence of KP extract to AGS cells viability at various incubation times and concentrations. Cells were co-cultured with different concentrations of KP extracts (8-128 µg/ml) and the cytotoxic effects were analyzed at 6 hours (A), 12 hours (B) and 24 hours (C) of incubation. Data are expressed as means  $\pm$  SD of three independent experiments. The significant difference compared to AGS cells and KP treated AGS cells were set at \*  $p < 0.05$

KP extract was not affected to cell viability at all incubation period, as demonstrated in the vehicle control group. Thus, KP extract affected to AGS cells viability in dose and time-dependent manners.

#### Anti-apoptosis property of the KP extract on *H. pylori*-infected AGS cells

##### 1. Effect of KP extract against caspase-3/7 activity at various times and conditions

Due to KP extract at 8 and 16 µg/ml had no cytotoxic effects against AGS cells, the subsequent determination of caspase-3/7 level was performed at various times among co-culture, pre-treatment with KP extract and pre-infection with *H. pylori*. Both concentrations of KP extract significantly inhibited caspase-3/7 activity at all incubation period of co-culture. The inhibitory activity of KP extracts at 8 and 16 µg/ml were 53.9% and 75.13%, 64.2% and 81.3%, 45.8% and 85.5% at 6, 12 and 24 hours, respectively (Figure 2A). The preventive and therapeutic effects of KP extract were initially determined at 6 and 12 hours. In pre-treated groups, both 8 and 16 µg/ml of KP extract lacked preventive action against caspase-3/7 activity. After washout of KP extract, *H. pylori* were still capable to activated caspase-3/7 activity in AGS cells at 12 hours (Figure 2B). On the contrary, pre-infected condition,


KP extract at 8 and 16 µg/ml significantly inhibited 80.6% and 90.5% of caspase-3/7 activation, respectively, at 12 hours (Figure 2C). The upmost %DMSO showed no effect to caspase-3/7 activity at all times.

##### 2. Effects of KP extract against caspase-8 activity

According to caspase-3/7 activity was markedly inhibited at 16 µg/ml of KP extract, the inhibitory effect against caspase-8 synthesis was further carried out at 16 and 32 µg/ml. As result in Figure 3, the level of caspase-8 enzyme does not difference between *H. pylori* infected and uninfected AGS cells. At 32 µg/ml of KP extract significantly inhibited the production of caspase-8 enzyme only in infected AGS cells with 47.3% inhibitory activity. However, KP extract tend to reduce caspase-8 synthesis. At 16 µg/ml of KP extract showed 24.2% inhibitory activity in infected AGS cells and 32 µg/ml of KP extract revealed 25.8% inhibitory activity in uninfected AGS cells. The highest concentration of 0.032% DMSO solubilized in KP extract was not affected to caspase-8 activity.

##### 3. KP extract irresponsible to *H. pylori* induced DNA fragmentation

As in Figure 4, *H. pylori* infection extremely activated DNA fragmentation at all incubation




**Figure 2** Effect of KP extract at 8 and 16 µg/ml against caspase-3/7 activity on uninfected and *H. pylori* infected AGS cells in various culture conditions and time points. Cells were co-cultured (A) at 6, 12, and 24 hours; pre-treated (B) at 6 and 12 hours; pre-infected (C) at 12 hours. The mixture of supernatant and lysate was determined for caspase-3/7 activity. Data are expressed as means  $\pm$  SD of two independent experiments. The significant difference compared to AGS cells and *H. pylori* infected AGS cells were set at \*  $p < 0.05$

times. The level of DNA fragmentation was gradually increased by *H. pylori* induction from 6 to 24 hours. However, KP extract at 8 and 16 µg/ml failed to inhibit DNA fragmentation in *H. pylori* induced AGS cells at every time points.


## DISCUSSION

*H. pylori* induced cell apoptosis is one of the most important mechanism of gastric cancer development. Two majors independent apoptotic

signaling pathways are death receptor and mitochondrial pathways which activate various caspase enzymes including caspase-3, caspase-8 and caspase-9 [30]. In our study found that *H. pylori* enhanced apoptosis in AGS cells greatly through caspase-3/7 not caspase-8. The level of caspase-3/7 activity was more obviously boost up than caspase-8 in *H. pylori*-infected compared to uninfected AGS cells. Our data strongly supported that the major apoptotic process in *H. pylori* mediated through the



**Figure 3** Effect of KP extract against caspase-8 activity on AGS cells and *H. pylori* infected AGS cells. Cells were co-cultured with *H. pylori* and KP extract at 16 and 32 µg/ml for 24 hours. The mixture of supernatant and lysate was determined for caspase-8 activity. Data are expressed as means ± SD of two independent experiments. The significant difference from control of each group was set at \*  $p < 0.05$



**Figure 4** Effect of KP extract against DNA fragmentation on AGS cells and *H. pylori* infected AGS cells. Cells were co-cultured with *H. pylori* and KP extract at 8 and 16 µg/ml for 6, 12 and 24 hours. The lysate was determined for mono- and oligonucleosomes released. Data are expressed as means ± SD of two independent experiments. The significant difference from control of each group was set at \*  $p < 0.05$

mitochondrial pathway and independent of caspase-8 activation. Similarly, caspase-8 did not involve in *H. pylori* associated-apoptosis in SGC-7901 cells. Only 20% of the apoptosis rate was reduced by

caspase-8 inhibitor while caspase-3 and 9 inhibitors significantly suppressed apoptosis rate at 72% and 45%, respectively [31]. Recently, *H. pylori* was found to inhibit the cleavage of tumor necrosis

factor receptor-associated factor 1 (TRAF1) and caspase-8 activation via cagA dependent mechanism or via other signaling pathways mediated by activation of NF-kB [32]. In addition, vacA N-terminal peptide could activate cytochrome c release and procaspase-3 as determined by poly (ADP-ribose) polymerase (PARP) cleavage [33].

Since the antibiotic resistance is problematic for recent *H. pylori* treatment [34], herbal medicines have become the alternative treatment for *H. pylori* infection by their several pharmacological activities [35]. *Kaempferia parviflora* (KP) is commonly found in Asia including Thailand and used as a traditional remedy to treat gastrointestinal disorders for a long time. In this study, the ethyl acetate extract of KP showed time and concentration effect on survival of AGS cells. However, 8 and 16 µg/ml of KP extract does not displayed significant cytotoxic action even at 24 hours. Similarly, KP maceration extract at 20 µg/ml affected AGS cell viability only 10% at 48 hours [36]. Interestingly, our KP extract significantly inhibited both caspase-3/7 and caspase-8 synthesis in *H. pylori* infected and uninfected AGS cells. KP extract showed superior suppressive action against caspase-3/7 in co-culture and pre-infected conditions which benefit for its therapeutic purpose in *H. pylori* infected patient. While, the preventive action was not noticed with KP extract, the caspase-3/7 activation was still induced by *H. pylori* in pre-treated KP extract to AGS cells. The low concentration of KP ethanolic extract (10 and 20 µg/ml) expressed anti-apoptosis function in U937 cell, but high concentration (80 and 100 µg/ml) induced apoptosis through caspase-3 activation [37]. KP.8.10 or 5,7,4-trimethoxyflavone, a bioactive compound of KP extract, significantly increased caspase-3 activity at 18 hours in cholangiocarcinoma cell lines [38]. However, DNA fragmentation which is a hallmark of apoptosis could not suppressed by our KP extract in *H. pylori* induced AGS cells even 24 hours of co-culture. This result supported that the caspase-independent cell apoptosis plays a major role in DNA fragmentation in *H. pylori* infected tissues especially the intrinsic activation of reactive oxygen radicals through mitochondria pathway [39]. Several investigators have investigated the regulation of *H. pylori* induced apoptosis leading to releasing of cytochrome c, apoptosis-inducing factor (AIF) and endonuclease-G (ENDO-G) from mitochondria [40]. Moreover, the vacA toxin of *H. pylori* can efficiently trigger apoptosis by dissipation of mitochondrial membrane potential,

recruitment of Bax and Bak, and release of cytochrome c into the cytosol [9]. Although, KP extract could inhibit the activity of caspase-3/7 and caspase-8, the effect of KP extract has to be further elucidated against other mitochondrial pathways in order to effectively inhibit downstream apoptotic events.

## CONCLUSION

Our results demonstrate that *H. pylori* infection activates apoptosis using caspases-independent as the main pathway. KP ethyl acetate extract exhibited less cytotoxicity with time and dose-dependent and significantly suppressed caspase-8 and caspase-3/7 activities in both of *H. pylori* infected AGS cells and uninfected cell. Further investigation should be carried out for a better understanding of *H. pylori* induced-apoptosis pathway and anti-apoptotic response of KP ethyl acetate extract.

## ACKNOWLEDGEMENTS

This work was partially supported by Faculty of Allied Health Sciences, Chulalongkorn University (AHS-CU 59009) and the 90<sup>th</sup> Anniversary Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund). This study was received scholarship from the Graduate School, Chulalongkorn University to commemorate the 72<sup>th</sup> anniversary of his Majesty King Bhumibol Adulyadej.

## REFERENCES

1. Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. *World J Gastroenterol*. 2014 Apr 28; 20(16): 4483-90. doi: 10.3748/wjg.v20.i16.4483
2. Hoang TT, Bengtsson C, Phung DC, Sorberg M, Granstrom M. Seroprevalence of *Helicobacter pylori* infection in urban and rural Vietnam. *Clin Diagn Lab Immunol*. 2005 Jan; 12(1): 81-5. doi: 10.1128/CDLI.12.1.81-85.2005
3. Deankanob W, Chomvarin C, Hahnvajanawong C, Intapan PM, Wongwajana S, Mairiang P, et al. Enzyme-linked immunosorbent assay for serodiagnosis of *Helicobacter pylori* in dyspeptic patients and volunteer blood donors. *Southeast Asian J Trop Med Public Health*. 2006 Sep; 37(5): 958-65.
4. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of *Helicobacter pylori* Infection in Adults. *Gastroenterology*. 2016;151(1):51-69.
5. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. *Aliment Pharmacol Ther*. 2016 Feb; 43(4): 514-33. doi: 10.1111/apt.13497

6. Ma HY, Liu XZ, Liang CM. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. *World J Gastroenterol*. 2016 Aug; 22(29): 6619-28. doi: 10.3748/wjg.v22.i29.6619
7. Eisenman ST, Gibbons SJ, Verhulst PJ, Cipriani G, Saur D, Farrugia G. Tumor necrosis factor alpha derived from classically activated "M1" macrophages reduces interstitial cell of Cajal numbers. *Neurogastroenterol Motil*. 2017 Apr; 29(4). doi: 10.1111/nmo.12984
8. Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. *Physiol Rev*. 2014 Apr; 94(2): 329-54. doi: 10.1152/physrev.00040.2012
9. Rassow J. *Helicobacter pylori* vacuolating toxin A and apoptosis. *Cell Commun Signal*. 2011 Nov; 9: 26. doi: 10.1186/1478-811X-9-26
10. Kim JM, Kim JS, Kim N, Ko SH, Jeon JI, Kim YJ. *Helicobacter pylori* vacuolating cytotoxin induces apoptosis via activation of endoplasmic reticulum stress in dendritic cells. *J Gastroenterol Hepatol*. 2015 Jan; 30(1): 99-108. doi: 10.1111/jgh.12663
11. Tiwari S, Ghoshal U, Ghoshal UC, Dhingra S, Pandey R, Singh M, et al. *Helicobacter pylori*-induced apoptosis in pathogenesis of gastric carcinoma. *Indian J Gastroenterol*. 2005 Sep-Oct; 24(5): 193-6.
12. Chaudhari AA, Seol JW, Kim SJ, Lee YJ, Kang HS, Kim IS, et al. Reactive oxygen species regulate Bax translocation and mitochondrial transmembrane potential, a possible mechanism for enhanced TRAIL-induced apoptosis by CCCP. *Oncol Rep*. 2007 Jul; 18(1): 71-6.
13. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal*. 2014 Mar; 20(7): 1126-67. doi: 10.1089/ars.2012.5149
14. Mizuki I, Shimoyama T, Fukuda S, Liu Q, Nakaji S, Munakata A. Association of gastric epithelial apoptosis with the ability of *Helicobacter pylori* to induce a neutrophil oxidative burst. *J Med Microbiol*. 2000 Jun; 49(6): 521-4. doi: 10.1099/0022-1317-49-6-521
15. Scotiniotis IA, Rokkas T, Furth EE, Rigas B, Shiff SJ. Altered gastric epithelial cell kinetics in *Helicobacter pylori*-associated intestinal metaplasia: implications for gastric carcinogenesis. *Int J Cancer*. 2000 Jan; 85(2): 192-200.
16. Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by *Helicobacter pylori* infection: implications in gastric carcinogenesis. *Am J Gastroenterol*. 2001 Jan; 96(1): 16-26. doi: 10.1111/j.1572-0241.2001.03447.x
17. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with *Helicobacter pylori* infection increases risk of gastric cancer. *Int J Cancer*. 2004 Mar; 109(1): 138-43. doi: 10.1002/ijc.11680
18. Lee KE, Khoi PN, Xia Y, Park JS, Joo YE, Kim KK, et al. *Helicobacter pylori* and interleukin-8 in gastric cancer. *World J Gastroenterol*. 2013 Dec; 19(45): 8192-202. doi: 10.3748/wjg.v19.i45.8192
19. Stamatis G, Kyriazopoulos P, Golegou S, Basayiannis A, Skaltsas S, Skaltsa H. In vitro anti-*Helicobacter pylori* activity of Greek herbal medicines. *J Ethnopharmacol*. 2003 Oct; 88(2-3): 175-9.
20. Pandey MM, Rastogi S, Rawat AK. *Saussurea costus*: botanical, chemical and pharmacological review of an ayurvedic medicinal plant. *J Ethnopharmacol*. 2007 Apr; 110(3): 379-90. doi: 10.1016/j.jep.2006.12.033
21. Plengsuriyakarn T, Viyanant V, Eursitthichai V, Picha P, Kupradinun P, Itharat A, et al. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. *BMC Complement Altern Med*. 2012 Mar; 12: 23. doi: 10.1186/1472-6882-12-23
22. Cellini L, Di Campli E, Masulli M, Di Bartolomeo S, Allocati N. Inhibition of *Helicobacter pylori* by garlic extract (*Allium sativum*). *FEMS Immunol Med Microbiol*. 1996 Apr; 13(4): 273-7.
23. Bae EA, Han MJ, Baek NI, Kim DH. In vitro anti-*Helicobacter pylori* activity of panaxytriol isolated from ginseng. *Arch Pharm Res*. 2001 Aug; 24(4): 297-9.
24. Mahady GB, Pendland SL, Yun GS, Lu ZZ, Stoia A. Ginger (*Zingiber officinale Roscoe*) and the gingerols inhibit the growth of Cag A+ strains of *Helicobacter pylori*. *Anticancer Res*. 2003 Sep-Oct; 23(5a): 3699-702.
25. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against *Helicobacter pylori* isolates from India and during infections in mice. *Antimicrob Agents Chemother*. 2009 Apr; 53(4): 1592-7. doi: 10.1128/AAC.01242-08
26. Saokaew S, Wilairat P, Raktanyakan P, Dilokthornsakul P, Dhippayom T, Kongkaew C, et al. Clinical Effects of *Kaempferia parviflora*: A Systematic Review. *J Evid Based Complementary Altern Med*. 2017; 22(3): 413-28. doi: 10.1177/2156587216669628
27. Tewtrakul S, Subhadhirasakul S. Effects of compounds from *Kaempferia parviflora* on nitric oxide, prostaglandin E2 and tumor necrosis factor-alpha productions in RAW264.7 macrophage cells. *J Ethnopharmacol*. 2008 Oct; 120(1): 81-4. doi: 10.1016/j.jep.2008.07.033
28. Rujjanawate C, Kanjanapothi D, Amornlerdpison D, Pojanagaroon S. Anti-gastric ulcer effect of *Kaempferia parviflora*. *J Ethnopharmacol*. 2005 Oct; 102(1): 120-2. doi: 10.1016/j.jep.2005.03.035
29. Chaichanawongsaroj N, Amonyngcharoen S, Pattiyathane P, Vilaichone R-k, Poovorawan Y. Anti-*Helicobacter pylori* and anti-internalization activities of Thai folk remedies used to treat gastric ailments. *Journal of Medicinal Plants Research*. 2012; 6(8): 1389-93. doi: 10.5897/jmpr10.552
30. Potthoff A, Ledig S, Martin J, Jandl O, Cornberg M, Obst B, et al. Significance of the caspase family in *Helicobacter pylori* induced gastric epithelial apoptosis. *Helicobacter*. 2002 Dec; 7(6): 367-77.
31. Zhang H, Fang DC, Lan CH, Luo YH. *Helicobacter pylori* infection induces apoptosis in gastric cancer cells through the mitochondrial pathway. *J Gastroenterol*

- Hepatol. 2007 Jul; 22(7): 1051-6. doi: 10.1111/j.1440-1746.2007.04959.x
32. Wan XK, Yuan SL, Wang YC, Tao HX, Jiang W, Guan ZY, et al. *Helicobacter pylori* inhibits the cleavage of TRAF1 via a CagA-dependent mechanism. *World J Gastroenterol.* 2016 Dec; 22(48): 10566-74. doi: 10.3748/wjg.v22.i48.10566
  33. Galmiche A, Rassow J, Doye A, Cagnol S, Chambard JC, Contamin S, et al. The N-terminal 34 kDa fragment of *Helicobacter pylori* vacuolating cytotoxin targets mitochondria and induces cytochrome c release. *EMBO J.* 2000 Dec; 19(23): 6361-70. doi: 10.1093/emboj/19.23.6361
  34. Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat *Helicobacter pylori* antibiotic resistance: an Asian perspective. *Molecules.* 2015 Apr; 20(4): 6068-92. doi: 10.3390/molecules20046068
  35. Zaidi SF, Muhammad JS, Usmanghani K, Sugiyama T. Review: Pharmacological ins and outs of medicinal plants against *Helicobacter pylori*: A review. *Pak J Pharm Sci.* 2015 May; 28(3 Suppl): 1171-6.
  36. Wongsrikaew N, Kim H, Vichitphan K, Cho SK, Han J. Antiproliferative activity and polymethoxyflavone composition analysis of *Kaempferia parviflora* extracts. *J Korean Soc Appl Biol Chem.* 2012 Dec; 55(6): 813-7. doi: 10.1007/s13765-012-2175-5
  37. Banjerdpongchai R, Chanwikruy Y, Rattanapanone V, Sripanidkulchai B. Induction of apoptosis in the human Leukemic U937 cell line by *Kaempferia parviflora* Wall.ex.Baker extract and effects of paclitaxel and camptothecin. *Asian Pac J Cancer Prev.* 2009; 10(6): 1137-40.
  38. Leardkamolkarn V, Tiamyuyen S, Sripanidkulchai BO. Pharmacological activity of *Kaempferia parviflora* extract against human bile duct cancer cell lines. *Asian Pac J Cancer Prev.* 2009 Oct-Dec; 10(4): 695-8.
  39. Calvino-Fernandez M, Benito-Martinez S, Parra-Cid T. Oxidative stress by *Helicobacter pylori* causes apoptosis through mitochondrial pathway in gastric epithelial cells. *Apoptosis.* 2008 Oct; 13(10): 1267-80. doi: 10.1007/s10495-008-0255-0
  40. Ashktorab H, Dashwood RH, Dashwood MM, Zaidi SI, Hewitt SM, Green WR, et al. *H. pylori*-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria. *Helicobacter.* 2008 Dec; 13(6): 506-17. doi: 10.1111/j.1523-5378.2008.00646.x